Explore the latest research on brain waste clearance and its implications for the $20B neurodegenerative disease market and future therapeutic developments.
Analyzing the clinical and regulatory implications of Retatrutide for GLP-1 muscle loss and the risks of off-label prescribing in the obesity treatment market.
Experts advocate rebranding PCOS to PMOS to address metabolic dysregulation. Explore the implications for diagnostic protocols, pharma R&D, and clinical pathways.